Randomized, Double-blind, Placebo-controlled Clinical Trial for the Evaluation of the Efficacy and Safety of Artemisia and Green Tea Extract SD1003F in Volunteers with Helicobacter pylori-associated Gastric Discomfort

BACKGROUND/AIMS: A previous study showed that dietary intervention with Artemisia and green tea extracts, i.e., SD1003F, relieved Helicobacter pylori-associated chronic atrophic gastritis in a mouse model. We continue the research through the current randomized double-blind clinical trial to evaluate the efficacy and safety of the intervention for H. pylori-associated gastric discomfort. MATERIALS AND METHODS: Forty-nine volunteers who tested positive for H. pylori infection received either placebo or SD1003F for 10 weeks and their functional dyspepsia-related quality of life (QOL) was evaluated. H. pylori infection using a urea breath test (UBT), measurement of pepsinogen level using GastroPanel. Adverse effects with biochemical changes were also evaluated. RESULTS: SD1003F administration significantly improved health related-QOL, including dietary intake, emotional stability, life pattern, and social factors relevant to gastric discomfort, in comparison to the control (P < 0.05). The mean UBT measurement significantly decreased in the SD1003F group (P < 0.05). In 2 of the 24 volunteers, SD1003F alone eradicated H. pylori infection, with significant improvements in endoscopic findings. GastroPanel analysis revealed significant improvements that reflect rejuvenation of gastric atrophy in the SD1003F group. No significant side effect was observed in any participant. CONCLUSIONS: SD1003F (Artemisia and green tea extract), is a potential phytochemical to improve H. pylori-associated gastric discomfort.

Clinical Implications of the Expression of Survivin and p53 in Superficial Transitional Cell Carcinoma of the Bladder / 대한비뇨기과학회지

PURPOSE: The prognostic value of p53 remains controversial in transitional cell carcinomas of the bladder. Survivin, an inhibitor of apoptosis, is expressed in many human cancers. Recent studies have reported increased expression of survivin in superficial transitional cell carcinomas of the bladder. We investigated the expression of survivin and p53 and the clinical implications of this expression in superficial transitional cell carcinomas of the bladder. MATERIALS AND METHODS: Immunohistochemical staining of paraffin sections using a monoclonal antibody for survivin and p53 was performed in 82 cases of superficial transitional cell carcinomas of the bladder. Correlations between the expression of survivin and p53 and clinicopathological features, such as age, multiplicity of tumor, size, recurrence, and progression, were examined. RESULTS: Among 82 cases, positive survivin expression (greater than 20%) was observed in 59 cases. Positive p53 expression (greater than 20%) was observed in 46 cases. There were no significant differences in age, gender, multiplicity, tumor size, tumor grade, pT stage, recurrence, or progression-free survival between p53-positive and p53-negative groups (p>0.05). Also, there were no significant differences in age, gender, multiplicity, tumor size, tumor grade, or pT stage between survivin-positive and survivin-negative groups (p>0.05). However, recurrent-free and progression-free survivals were significantly lower in the survivin-positive group than in the survivin-negative group (p<0.05). CONCLUSIONS: The expression of survivin can be recommended as a useful marker for predicting disease recurrence and progression. Survivin may be superior to p53 as a prognostic factor in superficial transitional cell carcinoma of bladder.

Long-Term Results of Transurethral Resection of the Prostate for Large Benign Prostatic Hyperplasia: A Comparative Study with Open Prostatectomy / 대한비뇨기과학회지

PURPOSE: We compare the effectiveness and safety of transurethral resection of the prostate(TURP) with those of open prostatectomy for large benign prostatic hyperplasia(BPH), that was over 70cc of prostate volume. MATERIALS AND METHODS: Seventy-one patients with a prostate volume of more than 70cc and who received TURP were classified to group A, while 41 patients who received open prostatectomy were classified to group B. The International Prostate Symptom Score(IPSS), maximal flow rate(Qmax) and post-voiding residual urine(PVR) volume were evaluated preoperatively and at 1, 3, 5 and over 5 years postoperatively. RESULTS: The postoperative IPSS, Qmax and PVR were significantly improved after 1 year(p0.05). The PVR was significantly lower in group B at 1 year post-operation(p0.05). There were 7 cases(9.8%) of re-operation and 3 cases(4.2%) of re-medication after 5 years of operation. There were no major complications for each group. CONCLUSIONS: On comparison between TURP and open prostatectomy for the patients with large BPH, there were no significant difference in effectiveness and safety for 5 years. Even for the patients with BPH that showed a high volume, TURP is an effective operation that can replace open prostatectomy.

Relationship between Acute Urinary Retention and Intraprostatic Inflammation in Benign Prostatic Hyperplasia / 대한비뇨기과학회지

PURPOSE: Acute or chronic prostatic inflammation exists to varying degrees in surgical specimens of prostates, extirpated for the treatment of benign prostatic hyperplasia(BPH). We investigated the relationship between acute urinary retention(AUR) and intraprostatic inflammation. MATERIALS AND METHODS: Between January 1997 and December 2006, 221 patients underwent transurethral resection of the prostate(TURP) for the treatment of BPH. The patients were divided into 2 groups based on the indication for surgery; an AUR group and a lower urinary tract symptoms (LUTS) group. The area of acute inflammation, the extent, and the aggressiveness of chronic inflammation were classified into four grades. The grades of inflammation, prostate volume, age, serum prostate-specific antigen(PSA), and prior medical treatment were compared between the two groups. All specimens were reviewed by one pathologist. RESULTS: The AUR group consisted of 106(47.9%) patients, and the LUTS group consisted of 115(52.1%) patients. There were no statistical differences between the two groups with respect to the mean values of the age, prostate size, and severity of chronic inflammation. There was a significant relationship between AUR and the areas of acute inflammation, and the extent of chronic inflammation(p=0.014 and p=0.003, respectively). The aggressiveness of chronic inflammation had no relationship with AUR (p=0.062). The serum PSA level was higher in the AUR group than the LUTS group(11.5 vs. 5.3ng/ml, respectively). CONCLUSIONS: The association for AUR with acute and chronic inflammation was stronger than that which existed with prostate size. Thus intraprostatic inflammation is an important risk factor in AUR.